Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 3.01 EUR 3.26% Market Closed
Market Cap: 240.5m EUR

EV/EBIT
Enterprise Value to EBIT

-39.4
Current
-24.3
Median
7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-39.4
=
Enterprise Value
202.9m EUR
/
EBIT
-5m EUR
All Countries
Close
EBIT Growth EV/EBIT to Growth
ES
Oryzon Genomics SA
MAD:ORY
Average EV/EBIT: 45.3
Negative Multiple: -39.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 064.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.6
13%
1.4
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
NL
argenx SE
XBRU:ARGX
60.4
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
190.8
N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-28.8
2-Years Forward
EV/EBIT
-449.7
3-Years Forward
EV/EBIT
-40.5